Narihito Seki
- Urology top 0.1%
- Urinary Bladder and Prostate Research 56
- Rheumatology top 0.5%
- Pelvic floor disorders treatments 28
-
- Prostate Cancer Diagnosis and Treatment 26
- Epidemiology top 5%
- Urinary Tract Infections Management 13
- Obstetrics and Gynecology top 5%
- Endometrial and Cervical Cancer Treatments 10
-
- Bladder and Urothelial Cancer Treatments 13
-
- Hormonal and reproductive studies 11
-
- Cancer Immunotherapy and Biomarkers 9
Narihito Seki
130 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 114
- Urology 1.9k
- Rheumatology 1.5k
- Pulmonary and Respiratory Medicine 803
- Epidemiology 795
- Obstetrics and Gynecology 168
Countries citing papers authored by Narihito Seki
This map shows the geographic impact of Narihito Seki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Narihito Seki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Narihito Seki more than expected).
Fields of papers citing papers by Narihito Seki
This network shows the impact of papers produced by Narihito Seki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Narihito Seki. The network helps show where Narihito Seki may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Narihito Seki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 9 | |
| 4 | 2022 | 6 | |
| 5 | 2022 | 1 | |
| 6 | 2021 | 17 | |
| 7 | 2021 | 9 | |
| 8 | 2021 | 2 | |
| 9 | 2021 | 19 | |
| 10 | 2010 | 1 | |
| 11 | 2010 | 9 | |
| 12 | 2008 | 8 | |
| 13 | PREDICTIVE FACTORS FOR THE EFFECT OF ALPHA1- ADRENOCEPTOR ANTAGONIST ON SUBJECTIVE AND OBJECTIVE PARAMETERS IN PATIENTS WITH NEUROGENIC LOWER URINARY TRACT DYSFUNCTION: SPECIAL FOCUS ON ALPHA1-D/A ADRENOCEPTOR ANTAGONIST NAFTOPIDIL | 2007 | 1 |
| 14 | 2006 | 56 | |
| 15 | 2006 | 17 | |
| 16 | 2005 | 13 | |
| 17 | 2003 | 3 | |
| 18 | 2001 | 11 | |
| 19 | 2001 | 110 | |
| 20 | 1988 | 25 |
About Narihito Seki
Narihito Seki is a scholar working on Urology, Rheumatology and Sensory Systems, having authored 134 papers that have together received 3.4k indexed citations. Recurring topics across this work include Urinary Bladder and Prostate Research (56 papers), Pelvic floor disorders treatments (28 papers), Prostate Cancer Diagnosis and Treatment (26 papers), Urinary Tract Infections Management (13 papers), Bladder and Urothelial Cancer Treatments (13 papers), Hormonal and reproductive studies (11 papers), Endometrial and Cervical Cancer Treatments (10 papers) and Cancer Immunotherapy and Biomarkers (9 papers). The work is most often cited by research in Urology (1.9k citations), Rheumatology (1.5k citations) and Pulmonary and Respiratory Medicine (803 citations). Narihito Seki has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Seiji Naito, Yukio Homma, Hidehiro Κakizaki, Osamu Yokoyama, Osamu Yamaguchi, Momokazu Gotoh, Osamu Nishizawa, Masayuki Takeda, Masaki Yoshida and Junichi Kodama. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Physiology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.